Login to Your Account


Amid uncertainties, Teva surprises with Nupathe counter bid

By Jennifer Boggs
Managing Editor

Thursday, January 9, 2014
With investors still awaiting the appointment of a new CEO following Jeremy Levin’s abrupt departure in October, Teva Pharmaceutical Industries Ltd. made an unsolicited $114 million cash offer for Nupathe Inc., starting a surprise bidding war with Endo Health Solutions, which inked a deal last month to acquire the small specialty pharma firm for $105 million in up-front cash.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription